Overview of Dr. Dunn
Dr. Lara Dunn is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 8 years. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 50 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
NYU Grossman School of MedicineResidency, Internal Medicine, 2009 - 2012
Perelman School of Medicine at the University of PennsylvaniaClass of 2009
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2011 - 2024
Clinical Trials
- Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Start of enrollment: 2018 Apr 30
- A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Start of enrollment: 2021 Jan 20
Roles: Principal Investigator, Contact
- A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Start of enrollment: 2022 Oct 06
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- 11 citationsHypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.Nancy Y Lee, Eric J Sherman, HeiKo Schöder, Rick Wray, Jay O Boyle
Journal of Clinical Oncology. 2024-03-10 - 212 citationsRandomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.Sean McBride, Eric J. Sherman, C. Jillian Tsai, Shrujal S. Baxi, Jahan Aghalar
Journal of Clinical Oncology. 2021-01-01 - 57 citationsPredictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: a Clinicopathologic Study with Correlation between MYB Fusion and Protein ExpressionBin Xu, Esther Drill, Allen S. Ho, Alan L. Ho, Lara Dunn
The American Journal of Surgical Pathology. 2017-10-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
